Scholarlink

<p>Mammalian cell lines are the preferred host cells for the biopharmaceutical industry. Chinese hamster ovary (CHO) and human embryonic kidney 293 (HEK293) cells are frequently utilized in the production of recombinant therapeutic proteins (RTPs) owing to their capacity to facilitate appropriate protein folding and perform accurate post-translational modifications (PTMs). However, there are still some bottlenecks in the biopharmaceutical process using mammalian cells, including lower productivity, higher production cost and increased risk of contamination compared with bacterial or yeast expression systems. In addition to vector, media and bioprocess optimization, advances in host cell engineering including gene overexpression, knockout and knockdown have significantly advanced cell-line development. Besides targeting known genes and pathways, miRNA engineering and omics analysis are also employed to enhance mammalian cell culture performance. Optimization of cell engineering and production processes further drives the development of more efficient mammalian cell expression systems. This review systematically summarizes key achievements in cell engineering and offers insights into potential targets and pathways for improving therapeutic protein production in mammalian cells.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells

  • 期刊论文

  • 发表日期：

    2025年11月20日

查看全文
  • Xi Zhang,
  • Yuan Shen,
  • Zihan Guo,
  • Yanfang Wang,
  • Xiaoyin Wang,
  • Tianyun Wang

摘要

Mammalian cell lines are the preferred host cells for the biopharmaceutical industry. Chinese hamster ovary (CHO) and human embryonic kidney 293 (HEK293) cells are frequently utilized in the production of recombinant therapeutic proteins (RTPs) owing to their capacity to facilitate appropriate protein folding and perform accurate post-translational modifications (PTMs). However, there are still some bottlenecks in the biopharmaceutical process using mammalian cells, including lower productivity, higher production cost and increased risk of contamination compared with bacterial or yeast expression systems. In addition to vector, media and bioprocess optimization, advances in host cell engineering including gene overexpression, knockout and knockdown have significantly advanced cell-line development. Besides targeting known genes and pathways, miRNA engineering and omics analysis are also employed to enhance mammalian cell culture performance. Optimization of cell engineering and production processes further drives the development of more efficient mammalian cell expression systems. This review systematically summarizes key achievements in cell engineering and offers insights into potential targets and pathways for improving therapeutic protein production in mammalian cells.